Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Prasugrel

Nature Reviews Drug Discovery volume 8, pages 449–450 (2009)Cite this article

Abstract

 Prasugrel

In February 2009, the antiplatelet therapy prasugrel (Efient; Daiichi Sankyo/Eli Lilly) was granted marketing authorization by the European Commission for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing primary or delayed percutaneous coronary intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Antiplatelet therapies.

References

  1. Bhatt, D. L. & Topol, E. J. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev. Drug Discov. 2, 15–28 (2003).

  2. Raju, N. C. et al. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clin. Pract. Cardiovasc. Med. 5, 766–780 (2008).

    Article  CAS  Google Scholar 

  3. Sugidachi, A. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 129, 1439–1446 (2000).

    Article  CAS  Google Scholar 

  4. Niitsu, Y. et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 31, 184–194 (2005).

    Article  CAS  Google Scholar 

  5. Jernberg, T. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166–1173 (2006).

    Article  CAS  Google Scholar 

  6. Brandt, J. T. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153, 66.e9–66.e16 (2007).

    Article  Google Scholar 

  7. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).

    Article  CAS  Google Scholar 

  8. European Medicines Agency (EMEA). European Public Assessment Report — Efient. EMEA website [online], (2009).

  9. Siller-Matula, J. et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb. Haemost. 97, 385–393 (2007).

    Article  CAS  Google Scholar 

  10. Collet, J. P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309–317 (2009).

    Article  CAS  Google Scholar 

  11. Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009).

    Article  CAS  Google Scholar 

  12. Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl J. Med. 360, 354–362 (2009).

    Article  CAS  Google Scholar 

  13. Ho, P. M. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937–944 (2009).

    Article  CAS  Google Scholar 

  14. Lau, W. C. & Gurbel, P. A. Antiplatelet drug resistance and drug–drug interactions: role of cytochrome P450 3A4. Pharm. Res. 23, 2691–2708 (2006).

    Article  CAS  Google Scholar 

  15. Farid, N. A. et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos. 35, 1096–1104 (2007).

    Article  CAS  Google Scholar 

  16. Antman, E. M. et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel — thrombolysis in myocardial infarction) analysis. J. Am. Coll. Cardiol. 51, 2028–2033 (2008).

    Article  CAS  Google Scholar 

  17. IMS MIDAS (2008).

  18. Arnold, C. J. et al. Credit Suisse Equity Research Report (Credit Suisse Securities LLC, 31 Mar 2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kurt Huber is at the 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria.,

    Kurt Huber

  2. Uma Yasothan and Bashar Hamad are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK.,

    Uma Yasothan & Bashar Hamad

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. kurt.huber@wienkav.at UYasothan@de.imshealth.com p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Kurt Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bashar Hamad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huber, K., Yasothan, U., Hamad, B. et al. Prasugrel. Nat Rev Drug Discov 8, 449–450 (2009). https://doi.org/10.1038/nrd2899

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2899

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing